Novo Integrated Sciences extends CEO resignation to March 31, 2025; Mattacchione to stay as Chairman

Novo Integrated Sciences, Inc.

CEO Robert Mattacchione's resignation, previously set for February 5, 2025 and extended twice, now extended to no later than March 31, 2025.
After stepping down as CEO, Mattacchione will remain Chairman of the Board and Chairman of subsidiary Novo Healthnet Limited.
Resignation is not due to any disagreement with company operations, policies, or practices.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Robert Mattacchione

Chief Executive Officer

Novo Integrated Sciences, Inc.

Effective: 2025-03-31
Filed: March 11, 2025, 7:59 PM ET

Following Mr. Mattacchione’s departure as Chief Executive Officer, Mr. Mattacchione intends to continue to serve as (i) the Company’s Chairman of the Board, and (ii) Chairman of Novo Healthnet Limited, a wholly owned subsidiary of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Mattacchione resigned as Chief Executive Officer at Novo Integrated Sciences, Inc..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

Following Mr. Mattacchione’s departure as Chief Executive Officer, Mr. Mattacchione intends to continue to serve as (i) the Company’s Chairman of the Board, and (ii) Chairman of Novo Healthnet Limited, a wholly owned subsidiary of the Company.

View on SEC.gov

Source: SEC EDGAR

accession 0001493152-25-009859

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.